Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022

Pfizer reports positive results from Echelon-3 study

Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,

Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals

Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

Fischer Medical Ventures and The Therapy Platform partner for mental healthcare

Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions

AxoSim appoints Alif Saleh as CEO

Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer

Suven to acquire a majority stake in CDMO player ‘Sapala Organics’

Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies

Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older

Lilly's tirzepatide was superior to placebo for MASH resolution

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine